TrialDiabetes, obesity & metabolism2017

Upper and/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: Incidence and consequences.

Michael Horowitz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.